Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of RELVAXA 20 vs Xarelto 20 mg under fed conditions in healthy Thai volunteers
TCTR20240813002Phase 1Completed
- Sponsor
- T.O. Chemicals
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of rivaroxaban in venous thromboembolism (VTE), Atrial fibrillation (AFib) and pulmonary embolism (PE) (2 arms), sponsored by T.O. Chemicals. Started Sep 2024; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)pulmonary embolism (PE)
Beyond the preview
Go deeper on TCTR20240813002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240813002.